ALK and non-small cell lung carcinoma: For example, according to our analysis and the meta-analysis of Cameron et al., for the 4–7% of ALK + NSCLC, introduction of ALK inhibitors resulted in a large increase in PFS and increase of ORR including patients with measurable baseline brain metastases when compared to chemotherapy [8].